NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
The award recognizes and supports promising female scientists working in mass spectrometry
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Women of all ages will get round-the-clock access to comprehensive treatment
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment
Proposed combination enhances Pfizer’s position as a leading company in oncology
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
